Home
Storia in 4 fonti
AstraZeneca's blood pressure pill approved, but competition could be around the corner
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
- ·
biopharmadive.com
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in…
- ·
endpoints.news
AstraZeneca's blood pressure pill approved, but competition could be around the corner
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
